China Approves Lumirix(R) for Additional Indication in Atopic Dermatitis

China Medical System Holdings Limited (CMS) announced that its subsidiary, Dermavon Holdings Limited, received approval from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (Lumirix(R)) for an additional indication of atopic dermatitis (AD). This approval offers a new topical treatment option for pediatric patients aged 2 years and older, adolescents, and adult AD patients.